StreetInsider.com News Articles

Form 8-K Turn Therapeutics Inc. For: Sep 10

Thu, 10 Sep 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27045556.html

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 10 Sep 2026 08:00:00 -0400

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:

Date: September 23, 2026
Time: 1:30 PM ET

The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well as a

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 10 Sep 2026 08:00:00 -0400

Date: September 23, 2026
Time: 1:30 PM ET

Form D Turn Therapeutics Inc.

Wed, 26 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260826/26982394.html

Turn Therapeutics publishes GX-03 skin inflammation study in mice

Thu, 20 Aug 2026 08:04:47 -0400

Turn Therapeutics Inc. (Nasdaq: TTRX) announced the publication of peer-reviewed research showing that its investigational topical therapy GX-03 reduced several inflammatory markers in a mouse model of atopic dermatitis-like skin disease.

The study, published in the journal Life, evaluated 40 mice that received either no pretreatment or four days of topical GX-03 before exposure to Staphylococcus aureus, a bacterial challenge known to trigger atopic dermatitis-like inflammation. Following predefined exclusions, 18 animals per group were included in the final analysis.

Animals pretreated with GX-03 showed a 66% reduction in clinical dermatitis severity compared with untreated controls. The study recorded reductions in IL-36α by

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Thu, 20 Aug 2026 08:00:00 -0400

In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%

Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Thu, 20 Aug 2026 08:00:00 -0400

Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established

Form 8-K Turn Therapeutics Inc. For: Aug 13

Tue, 18 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26941114.html

Form 8-K Turn Therapeutics Inc. For: Aug 14

Mon, 17 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260817/26938118.html

Form 10-Q Turn Therapeutics Inc. For: Jun 30

Wed, 12 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260812/26913863.html

Form 8-K Turn Therapeutics Inc. For: Aug 12

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913678.html

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics